Collier Nicholas J, Ali Faisal R, Lear John T
a Dermatology Centre, Salford Royal NHS Foundation Trust , University of Manchester, Manchester Academic Health Science Centre , Manchester , UK.
b St John's Institute of Dermatology , St Thomas' Hospital , London , UK.
Expert Rev Anticancer Ther. 2016 Oct;16(10):1011-8. doi: 10.1080/14737140.2016.1230020. Epub 2016 Sep 22.
Basal cell carcinomas (BCCs) are the commonest malignancy in the Western world. Locally advanced BCCs (laBCCs) represent tumours that have developed in difficult-to-treat facial sites, aggressively recurrent tumours, large neglected tumours and those in which current treatment options are excluded by clinical or patient-driven criteria. It is estimated laBCCs represent 1% of BCCs.
Sonidegib is an oral hedgehog pathway inhibitor with a novel structure. It has recently been licensed for the treatment of laBCC. This article provides a comprehensive review of the literature regarding sonidegib, detailing the pharmacology of the compound, clinical trial data, competitor compounds and a future perspective. Expert commentary: Sonidegib is a novel smoothened (SMO) inhibitor with comparable efficacy to vismodegib, with patient response rates of 44% (sonidegib) and 43% (vismodegib). The adverse effect profile of these two treatments is similar with the main effects being considered to be class effects of SMO inhibitors.
基底细胞癌（BCC）是西方世界最常见的恶性肿瘤。局部晚期基底细胞癌（laBCC）指在难以治疗的面部部位发生的肿瘤、侵袭性复发性肿瘤、长期被忽视的大肿瘤以及因临床或患者相关标准而排除现有治疗方案的肿瘤。据估计，laBCC占基底细胞癌的1%。
索尼德吉是一种具有新型结构的口服刺猬信号通路抑制剂。它最近已被批准用于治疗laBCC。本文对有关索尼德吉的文献进行了全面综述，详细介绍了该化合物的药理学、临床试验数据、竞争化合物以及未来展望。专家评论：索尼德吉是一种新型的 smoothened（SMO）抑制剂，疗效与维莫德吉相当，患者缓解率分别为44%（索尼德吉）和43%（维莫德吉）。这两种治疗的不良反应谱相似，主要不良反应被认为是SMO抑制剂的类效应。
